Schedule 13G ownership disclosure

Protalix BioTherapeutics Inc

Security class unavailable · CUSIP: 74365A309

Event date: 2020-03-12

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
3,332,754
Percent of class
9.9900%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902664-20-001614
Form type
SC 13G
Filer
HIGHBRIDGE CAPITAL MANAGEMENT LLC
CIK
CIK 919185
Filed
Mar 23, 2020
Reporting period
Mar 12, 2020
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub